YM 337

Drug Profile

YM 337

Alternative Names: SMART anti-platelet antibody

Latest Information Update: 04 May 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma; Yamanouchi
  • Class Antiplatelets; Monoclonal antibodies
  • Mechanism of Action GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Coronary artery restenosis; Stroke; Thrombosis

Most Recent Events

  • 04 May 2004 YM 337 is available for licensing (http://www.yamanouchi.com)
  • 01 Mar 2004 Discontinued - Phase-II for Coronary artery restenosis in Europe (Injection)
  • 01 Mar 2004 Discontinued - Phase-II for Coronary artery restenosis in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top